This is a single-center, double-arm, open-label, randomized feasibility study that will determine whether a novel clinical decision aid accessed via the electronic health record will be acceptable to both cancer survivors and their cardiologists, will favorably impact appropriate medication use and cardiac imaging surveillance, and will improve clinician and patient decision-making, perception, and behavior towards cardioprotective medication usage and cardiovascular disease imaging utilization.
Patients ≥18 years with a history of cancer.
Have not previously visited a cardiologist to assess cardiovascular risk after cancer diagnosis.
Clinically at intermediate, high, or very high risk for cardiovascular diseases determined based on imprecise clinical risk models, such as those used for cardiac dysfunction.
Ability to understand a written informed consent form, and willing to sign it prior to study registration.
Patient <18 years.
Without a personal history of cancer.
Existing cardiomyopathy diagnosed after cancer diagnosis.
Documented cognitive impairment.